)
Hester Biosciences is locked in upper circuit of 10% at Rs 488 on the National Stock Exchange (NSE) after the pharmaceutical company launches its PPR (Peste Des Petits Ruminants) vaccine and Goat Pox vaccine.
PPR vaccine is to be given annually to sheep and goats. PPR disease causes dysentery and death of the animal. It is therefore a disease of high economical importance worldwide.
With the launch of these vaccines as well as being the second largest poultry vaccine manufacturer in India, Hester has positioned itself to capitalise on upcoming opportunities in the animal health care industry globally as well as in India,” Hester Biosciences said in a media release.
“The world market for PPR vaccine is slated to be for Rs 300 crore annually. The Indian market is slated to be Rs 40 crore annually. The PPR vaccine will contribute toward also the disease eradication programs of the Government of India,” said Mr. Rajiv Gandhi, CEO & MD, Hester Biosciences.
Till 1006 hours, a combined 14,617 shares changed hands and there are pending buy orders for 3,339 shares on the NSE and BSE.
PPR vaccine is to be given annually to sheep and goats. PPR disease causes dysentery and death of the animal. It is therefore a disease of high economical importance worldwide.
With the launch of these vaccines as well as being the second largest poultry vaccine manufacturer in India, Hester has positioned itself to capitalise on upcoming opportunities in the animal health care industry globally as well as in India,” Hester Biosciences said in a media release.
“The world market for PPR vaccine is slated to be for Rs 300 crore annually. The Indian market is slated to be Rs 40 crore annually. The PPR vaccine will contribute toward also the disease eradication programs of the Government of India,” said Mr. Rajiv Gandhi, CEO & MD, Hester Biosciences.
Till 1006 hours, a combined 14,617 shares changed hands and there are pending buy orders for 3,339 shares on the NSE and BSE.
